We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human|
|Biochemical Assay (BCA)||1 Antibodies|
|Blocking Antibody (Inhibition)||3 Antibodies|
|Blocking Reagent (BR)||9 Antibodies|
|Cell-ELISA (cELISA)||1 Antibodies|
|Cellular Assay (CA)||1 Antibodies|
|Dot Blot (DB)||86 Antibodies|
|ELISA (Capture)||1 Antibodies|
|Enzyme Immunoassay (EIA)||55 Antibodies|
|Flow Cytometry (FACS)||180 Antibodies|
|Fluorescence Microscopy (FM)||1 Antibodies|
|Functional Studies (Func)||2 Antibodies|
|Immunoassay (IA)||1 Antibodies|
|Immunochromatography (IC)||25 Antibodies|
|Immunocytochemistry (ICC)||66 Antibodies|
|Immunoelectron Microscopy (IEM)||2 Antibodies|
|Immunofluorescence (IF)||150 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||236 Antibodies|
|Antigen||Epidermal Growth Factor Receptor (EGFR) Antibodies|
|Conjugate||This EGFR antibody is conjugated to APC Alternatives|
Intracellular Flow Cytometry (ICFC)
|6 references available|
|Supplier||Log in to see|
Product Details anti-EGFR AntibodyTarget Details EGFR Application Details Handling References for anti-EGFR Antibody (ABIN2658305) Images
|Purification||The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.|
Target Details EGFRProduct Details anti-EGFR Antibody Application Details Handling References for anti-EGFR Antibody (ABIN2658305) Images back to top
|Alternative Name||EGFR (EGFR Antibody Abstract)|
|Background||Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and member of the protein kinase superfamily that regulates cell growth and differentiation. EGFR binds EGF, TGF-α, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, GP30, and vaccinia virus growth factor - all members of the EGF family. Ligand binding induces EGFR dimerization and autophosphorylation, initiating the MAPK, Akt, and JNK signaling pathways. EGFR is expressed by epithelial and endothelial cells and is frequently expressed by epithelial carcinomas.|
|Research Area||Cancer, Tyrosine Kinases, Growth Factors, Hormones, Receptors|
|Pathways||NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway|
Application DetailsProduct Details anti-EGFR Antibody Target Details EGFR Handling References for anti-EGFR Antibody (ABIN2658305) Images back to top
|Application Notes||Optimal working dilution should be determined by the investigator.|
|Restrictions||For Research Use only|
HandlingProduct Details anti-EGFR Antibody Target Details EGFR Application Details References for anti-EGFR Antibody (ABIN2658305) Images back to top
|Buffer||Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Handling Advice||Protect from prolonged exposure to light. Do not freeze.|
|Storage Comment||The antibody solution should be stored undiluted between 2°C and 8°C.|
References for anti-EGFR Antibody (ABIN2658305)Product Details anti-EGFR Antibody Target Details EGFR Application Details Handling Images back to top
Dong, Wodziak, Lowe: "Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface." in: The Journal of biological chemistry, Vol. 290, Issue 13, pp. 8016-27, 2015 (PubMed).
Pasternack, Domogauer, Khullar et al.: "The advantage of antibody cocktails for targeted alpha therapy depends on specific activity." in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 55, Issue 12, pp. 2012-9, 2014 (PubMed).
Pao, Chmielecki: "Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer." in: Nature reviews. Cancer, Vol. 10, Issue 11, pp. 760-74, 2010 (PubMed).
da Cunha Santos, Shepherd, Tsao: "EGFR mutations and lung cancer." in: Annual review of pathology, Vol. 6, pp. 49-69, 2011 (PubMed).
Gusterson, Hunter: "Should we be surprised at the paucity of response to EGFR inhibitors?" in: The Lancet. Oncology, Vol. 10, Issue 5, pp. 522-7, 2009 (PubMed).
Mano, Humblet: "Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer." in: Nature clinical practice. Oncology, Vol. 5, Issue 7, pp. 415-25, 2008 (PubMed).
ImagesProduct Details anti-EGFR Antibody Target Details EGFR Application Details Handling References for anti-EGFR Antibody (ABIN2658305) back to top